JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1

Hepatology Research

Volumn 44, Issue SUPPL1, 2014, Pages 59-70

  Asahina, Yasuhiro ^a   Hayashi, Norio ^b   Hiramatsu, Naoki ^c   Izumi, Namiki ^d   Koike, Kazuhiko ^e   Kumada, Hiromitsu ^f   Kurosaki, Masayuki ^d   Oketani, Makoto ^g   Suzuki, Fumitaka ^f   Takikawa, Hajime ^h   Tanaka, Atsushi ^h   Tanaka, Eiji ⁱ   Tanaka, Yasuhito ^j   Tsubouchi, Hirohito ^k   Yotsuyanagi, Hiroshi ^e  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d MUSASHINO RED CROSS HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g KAGOSHIMA UNIVERSITY   (Japan)

^h TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^k Kagoshima City Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; SIMEPREVIR; TELAPREVIR; URSODEOXYCHOLIC ACID;

AGE; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RISK; CARCINOGENESIS; CLINICAL PRACTICE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; JAPAN; KIDNEY DYSFUNCTION; LIVER FIBROSIS; MALAISE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; SKIN MANIFESTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84891927286     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12272     Document Type: Article

References (18)

1. Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of H. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res 2013; 43: 1-34.
2. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery - an underexploited structural class. Nat Rev Drug Discov 2008; 7: 608-624.
3. Tsantrizos YS. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061 - from the NMR tube to the clinic. Biopolymers 2004; 76: 309-323.
4. Lenz O, Verbinnen T, Lin TI etal. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878-1887.
5. Lin TI, Lenz O, Fanning G etal. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53: 1377-1385.
6. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2013; doi: 10.1007/s00535-013-0875-1 [Epub ahead of print].
7. Fried MW, Buti M, Dore GJ etal. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-Naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929.
8. Zeuzem S, Berg T, Gane E etal. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial. J Hepatol 2012; 56: S1-2.
9. Hayashi N, Goto S. A study of the efficacy of combination therapy including simeprevir (TMC435) in the treatment of genotype 1 hepatitis C (CONCERTO-1 trial). Kanzo 2013; 54: A24.
10. Izumi N, Hayashi N, Goto S. A study of the efficacy of retreatment with simeprevir (TMC435) in the treatment of genotype 1 hepatitis C (CONCERTO-2/3 trial). Kanzo 2013; 54: A156.
11. Suzuki F, Hayashi N, Goto S, Kumada H. A study of the efficacy of combination therapy with simeprevir (TMC435), peginterferon α-2b and ribavirin in the treatment of genotype 1 hepatitis C (CONCERTO-4 trial). Kanzo 2013; 54: A157.
12. Jacobson I, Dore G, Foster G etal. Simeprevir (tmc435) with peginterferon/ribavirin for chronic HCV Genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58: S568.
13. Manns M, Marcellin P, Fred Poordad F etal. Simeprevir (TMC35) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58: S568.
14. Lawitz E, Forns X, Zeuzem S etal. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. Gastroenterology 2013; 144: S151.
15. Huisman M, Snoeys J, Monbaliu J etal. In vitro studies investigating the mechanism of interaction between tmc435 and hepatic transporters. Hepatology 2010; 52: 461A.
16. Pharma J. Antiviral agent "Sovriad capsule 100mg" package insert. 2013.
17. Lenz O, Fevery B, Vijgen L etal. TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analyses of the ASPIRE Trial. J Hepatol 2012; 56: S5.
18. Hara T, Akuta N, Suzuki F etal. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol 2013; 85: 1746-1753.